Early benefit assessment: Detailed analysis of all G-BA resolutions

The AMNOG monitor provides current, well-founded analyses of all early benefit assessments and an overview of the negotiated reimbursement prices in Germany. It is an indispensable tool for HTA, market access and pricing managers.
 

Unrivalled AMNOG Process Knowledge

Gain relevant insights from our summary analysis and our evaluation of all AMNOG resolutions. more >>

Every Resolution Reviewed in Detail

The AMNOG monitor includes detailed analyses of every sinlge benefit assessment since 2011. more >>

Reimbursement Price Trends

See the development of manufacturer's prices and yearly therapy costs of all products with negotiated reimbursement prices. more >>

Interactive Analysis

Our comprehensive online analysis tool helps answer your individual questions. more >>

Intelligent search

Search for answers in all G-BA resolutions, justifications, IQWiG assessments and much more >>

Discontinuations

 Keep track of benefit-assessed medicinal products no longer available in Germany.. more >>

 

Identify decision-paths and trends in early benefit assessment. The AMNOG monitor is indispensable for managers and decision-makers in market access, pricing and reimbursement. 

Contact us for more information! >>

 

Dear readers of the AMNOG Monitor,

The German parliamentary elections seem to signal a new era: The federal government will probably consist of a three-party alliance with the Greens and the Liberals. The SPD now has the best chance of leading the government in a so-called "traffic light coalition", having replaced the CDU as the strongest party. The Ministry of Health, which has been led by the CDU, will be reassigned. However, it is too early to speculate on the impact on healthcare and early benefit assessments.

The G-BA is increasingly using the instrument of collection of routine practice data (Anwendungsbegleitende Datenerhebung; AbDE) and commissioning IQWiG to prepare the respective concepts. Corresponding procedures were initiated in October 2021 for Tecartus® in mantle cell carcinoma (MCL), as well as for Risdiplam (Evrysdi®) in spinal muscular atrophia (SMA) and for Fedratinib (Inrebic®) in myelofibrosis (MF). For Inclisiran (Leqvio®) there is a partial exclusion from prescription according to Annex III AM-RL, except for patients with primary hypercholesterolaemia or dyslipidemia who require LDL apheresis.

Adjustments to reimbursement prices of AMNOG products were seen in October for Emicizumab (Hemlibra®), Glycopyrroniumbromid (Sialanar®), Lonoctocog alfa (Afstyla®), Nintedanib (Ofev®) and Melatonin Slenyto®. Baloxavir marboxil (Xofluza®) was withdrawn from the German market.

We thank you for your trust and we promise to continue to expand the AMNOG Monitor in 2022. Please feel free to contact us for an appointment if you require AMNOG-Monitor training.

Resolutions October 2021